To understand which factor plays a crucial role in the prevention of heart failure in the early phase after the start of treatment with SGLT2i, we studied changes in plasma B-type natriuretic peptide (BNP), which is the marker for heart failure and other parameters in patients with type 2 diabetes [24]. Here, NPPB is linked to heart failure.